Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

Wet AMD affects approximately five million patients worldwide and this patient population is continuing to grow. Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, the central area of the retina responsible for detailed vision. These blood vessels are often fragile and can leak blood and fluid below the macula, causing damage to the photoreceptors and vision loss. AMD, a disease associated with aging, gradually destroys a patient's vision. It is the most common cause of vision loss in patients aged 50 or older, and represents a market of over $1 billion annually.

Abnormalities in the vitreomacular interface (the interface of the vitreous and macula) have been implicated in wet AMD, and recent publications have demonstrated that approximately one-third of AMD patients have focal vitreomacular adhesion (VMA). VMA is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye, and research has found that this adhesion occurs in the same location as the wet AMD pathology.[1]

ThromboGenics is developing microplasmin as a non-surgical treatment for vitreomacular adhesion. Microplasmin has the potential to separate the vitreous from the retina and, as wet AMD is thought to result from the abnormal connection of the vitreous to the retina, it is therefore anticipated that microplasmin could potentially prevent the progression of this highly prevalent disease.

The MIVI 5 (Microplasmin for IntraVitreous Injection) trial is a P
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... found to be prevalent in cancer patients regardless of nutritional ... at Cancer Treatment Centers of America ... for vitamin D deficiency and aggressive vitamin D repletion should ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090612/CTCALOGO ) , ...
... Jazz Pharmaceuticals, (Nasdaq: JAZZ ) sodium oxybate ... and the core symptoms associated with fibromyalgia, according to Phase ... Sleep Societies meeting in Seattle, WA. These data have ... for use of sodium oxybate in the treatment of fibromyalgia. ...
Cached Medicine Technology:Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients 2Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 2Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 3Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 4Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 5
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... 25, 2014 Recently, LunaDress.co.uk has updated its blog ... related accessories. Now, all of the models at LunaDress.co.uk come with ... groom lifts the wedding veil can turn out to be a ... A wedding veil can always bring surprise to a wedding. On ... how to choose veils for a big day . , ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... December 25, 2014 Residents at ... Community, recently showed their generous spirit by providing ... Catawba County Parenting Network- Grandparents Raising Grandchildren program. ... gathered around the largest Christmas tree on the ... purchased by residents of the Abernethy Village Association ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... first to tackle different forms of the disease and help ... new vaccine is designed to trigger production of a range ... causing the disease. Scientists created the vaccine by ... types of malaria parasite, which is known to trigger production ...
... A vaccine to prevent anal cancer is safe and effective ... funded in part by the vaccine,s maker. Anal cancer ... sexually transmitted disease in the United States. Anal cancer is ... with HIV. , , Merck,s Gardasil vaccine is already ...
... 11-month-old partnership between UCSF and Pfizer, Inc., aimed at ... selected its first projects for funding and joint development. ... on experimental therapies developed by the UCSF scientists with ... hard-to-treat, often deadly conditions, including lung and prostate cancer. ...
... News) -- Moving to the beat of music actually helps ... Researchers at McMaster University in Canada played a series ... on an electronic drum pad while they listened while the ... whether the final beat was consistent with the preceding rhythm, ...
... WEDNESDAY, Oct. 26 (HealthDay News) -- The genes suspected of ... the developing brain before birth, according to a major genetic ... spotted hundreds of genetic differences between males and females still ... genes involved in the development of the brain, but now ...
... estimate, half of Americans are confronting a civil legal problem at ... advice, or an advocate in civil court, they may lose a ... They may lose out in a divorce, or in a billing ... those services depends not on their need but where they live, ...
Cached Medicine News:Health News:Multiple malaria vaccine offers protection to people most at risk 2Health News:HPV Vaccine Might Help Prevent Anal Cancers: Study 2Health News:UCSF-Pfizer partnership yields projects aimed at clinical trials 2Health News:UCSF-Pfizer partnership yields projects aimed at clinical trials 3Health News:UCSF-Pfizer partnership yields projects aimed at clinical trials 4Health News:Links to Mental Illness Seen in Fetal Brains: Study 2Health News:Access to legal aid depends a lot on where you live, report says 2Health News:Access to legal aid depends a lot on where you live, report says 3
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Effective spinal bracing is a critical component ... surgical stabilization. The Aspen® Lumbosacral Bracing System™ ... provide a high degree of immobilization, unparalled ... patients . . . even if they ...
Medicine Products: